HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Future Of CBD In Supplements: NDI Notification Looms As Regulatory Path

Executive Summary

Recent statement that FDA has not found evidence supporting CBD as GRAS for use in human or animal food potentially points to NDI notifications as the only option manufacturers, marketers and other businesses will have to convince agency about safety for CBD and other hemp-derived substances used in dietary supplements.

You may also be interested in...



Hemp Ingredient Filter Recommended Before Lawful Use Allowed In Supplements In US

Filling in the blanks for which ingredients qualify for definition of hemp could be as difficult and complicated as the question of lawful use, says food and drug attorneys. A DEA rule from legislation de-scheduling hemp left room for confusion on which substances qualify. 

Emerging US Cannabinoid Market Sales Driver Could Drive Lawful Use Legislation Off The Rails

Delta-8 THC is a close chemical cousin to the substance recognized for intoxicating effects. Its effects aren't a settled question, along with whether it meets definition of hemp stated in 2018 farm bill.

Cannabinoid NDI Notification Failures Thicken Regulatory Cloud Over US Market

Clarity needed to remove unlawful label for using hemp- and cannabis-derived ingredients in supplements and food available in US. Rejections of two CBD NDI notifications could sour other firms on complying with requirement for cannabinoids or other ingredients, says food and drug law attorney Kristi Wolff.

Related Content

Topics

UsernamePublicRestriction

Register

RS149486

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel